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Coronary Flow Velocity Reserve After Percutaneous
Interventions Is Predictive of Periprocedural Outcome
M. Albertal, MD; M. Voskuil, MD; J.J. Piek, MD, PhD; B. de Bruyne, MD, PhD;
G. Van Langenhove, MD, PhD; P.I. Kay, MD; M.A. Costa, MD, PhD; E. Boersma, PhD;
T. Beijsterveldt, MD; J.E. Sousa, MD; J.A. Belardi, MD; P.W. Serruys, MD;
on Behalf of the Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group
Background—Because heterogeneous results have been reported, we assessed coronary flow velocity changes in
individuals who underwent percutaneous transluminal coronary angioplasty (PTCA) and examined their impact on
clinical outcome.
Methods and Results—As part of the Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II study, 379
patients underwent Doppler flow–guided angioplasty. All patients were evaluated according to their coronary flow
velocity reserve (CFVR) results (2.5 or 2.5) at the end of the procedure. A CFVR 2.5 after angioplasty was
associated with an elevated baseline blood flow velocity in both the target artery and reference artery. CFVR before
PTCA and CFVR in the reference artery were independent predictors of an optimal CFVR after balloon angioplasty
(CFVR before PTCA: odds ratio [OR], 2.26; 95% confidence interval [CI], 1.57 to 3.24; CFVR in reference artery: OR,
1.90; 95% CI, 1.21 to 2.98; both P0.001) and stent implantation (before PTCA: OR, 2.54; 95% CI, 1.47 to 4.36;
reference artery: OR, 1.97; 95% CI, 1.07 to 3.87; both P0.05). A low CFVR at the end of the procedure was an
independent predictor of major adverse cardiac events (MACE) at 30 days (OR, 4.71; 95% CI, 1.14 to 25.92; P0.034)
and at 1 year (OR, 2.06; 95% CI, 1.16 to 3.66; P0.014). After excluding MACE at 30 days, no difference in MACE
at 1 year was observed between the patients with and without a CFVR 2.5 at the end of the procedure.
Conclusions—A low postprocedural CFVR was associated with a worse periprocedural outcome (which was related to
microcirculatory disturbances), but there was no significant difference at late follow-up. (Circulation. 2002;105:1573-
1578.)
Key Words: angiography  imaging  microcirculation
Coronary flow velocity reserve (CFVR) has been used inthe catheterization laboratory to assess the significance
of physiological stenosis and the changes in coronary blood
flow after balloon angioplasty.1 The Doppler Endpoints
Balloon Angioplasty Trial Europe (DEBATE) I recently
demonstrated that the recurrence of clinical events after
percutaneous transluminal coronary angioplasty (PTCA) was
markedly larger in patients with a CFVR 2.5 (24% versus
12%).2
The DEBATE II clinical trial was designed to test the value
of a strategy of provisional stenting, which was defined as
stenting only when suboptimal angiographic and CFVR
results were observed after angioplasty, compared with a
strategy of elective stenting. In patients in the DEBATE II
study, in whom the CFVR was monitored throughout the
procedure, we analyzed the clinical predictive value of CFVR
for major adverse cardiac events (MACE) at short and
long-term follow-up. In addition, we evaluated the mecha-
nisms and predictors of an optimal CFVR result after percu-
taneous interventions.
Methods
Patient Selection and Study Objectives
In summary, patients scheduled to undergo single native coronary
angioplasty who were amenable for stent implantation were eligible
for the DEBATE II trial. Patients with total coronary occlusion or
ostial, bifurcated, or tortuous lesions were excluded from the study,
as were patients with previous Q-wave infarction in the myocardial
territory supplied by the target vessel or evolving myocardial
infarction (MI) in the previous week. Every patient provided written,
informed consent
A total of 618 patients recruited in DEBATE II were randomized
to elective stenting (n97) and CFVR and quantitative coronary
angiography (QCA)–guided coronary angioplasty (n521). Patients
without Doppler flow data available (n13) or who underwent
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bailout stenting (n129) were excluded from the guided-angioplasty
group.
Regardless of the CFVR results after balloon angioplasty, the
remaining 379 patients underwent a second randomization to addi-
tional stenting (n187) or no further treatment (n192). In the
present study, the guided-angioplasty group (n379) was divided
according to the absolute CFVR results at the end of the percutane-
ous intervention: optimal was defined as a CFVR 2.5 (n240) and
suboptimal as a CFVR 2.5 (n139). In contrast to the DEBATE II
study protocol, in the present study, QCA data after PTCA were not
used to define optimal and suboptimal groups.
Guided Balloon Angioplasty
In all patients, QCA and CFVR measurements were performed
throughout the procedure to achieve an optimal result according to
the above-mentioned preset criteria.
Optimal CFVR and QCA were defined as 2.5 and a percentage
diameter stenosis 35%, respectively. An “optimal result” (QCA
and CFVR) was expected to be achieved by increasing the size of the
balloon and/or increasing the inflation pressure. Bailout stenting was
allowed in the following situations: a residual stenosis 50%;
dissection type D, E, or F; persistent myocardial ischemia along with
a dissection type C; drop in TIMI flow grade of at least 1 grade; or
TIMI grade 0 or 1. After an optimal result was achieved or when
further attempts to improve the result were deemed unsafe by the
operator, the final diameter stenosis and CFVR were assessed.
Thereafter, and irrespective of these measurements, the second
randomization was performed.
Quantitative Coronary Angiography
At least 2 cine angiograms were performed before the procedure and
then repeated in the same projections at the end of the procedure.
QCA was performed using edge detection contour (CAAS II
system), as described previously.
CFVR Measurement
A 0.014-inch Doppler guidewire (Cardiometrics FloWire; EndoSon-
ics) was used.3 The Doppler wire was advanced distal to the lesion,
and velocity recordings were obtained under basal and hyperemic
conditions. Maximal hyperemia was induced by an intracoronary
bolus injection (12 g for the right coronary artery and 18 g for the
left coronary artery) or intravenous infusion (140 g · kg–1 · min–1)
of adenosine. Target vessel Doppler measurements were performed
before and after angioplasty and again after stent implantation. In
addition, Doppler measurements of an adjacent angiographically
normal vessel (30% diameter stenosis) were performed. Absolute
CFVR was calculated as the ratio of hyperemic to baseline time-
averaged peak velocity. Relative CFVR was calculated as the ratio of
the absolute CFVR in the target vessel to the absolute CFVR in the
reference artery.4 The CFVR was considered normalized when the
relative CFVR was 0.8.5,6
End Points
For the DEBATE II study, the efficacy end point was a composite of
MACE within 12 months of the procedure and included death from
any cause, nonfatal MI, and percutaneous or surgical target lesion
revascularization. MI was defined as the development of a new
Q-wave or a 2-fold rise of serum creatinine kinases, together with an
abnormal plasma level of myocardial isoenzymes. Enzymes were
systematically sampled twice within the first 24 hours. After hospital
discharge, patients were seen at the outpatient clinic at 1, 6, and 12
months. Each visit included the recording of the angina status, the
cardiac medications, a 12-lead ECG, and a complete physical
examination. No follow-up angiogram was performed unless clini-
cally indicated.
Statistical Analysis
Continuous variables are expressed as meanSD, and differences
between groups of patients were studied using the unpaired Student’s
t test or one-way ANOVA, whichever was appropriate. Categorical
variables are presented as percentages, and differences between
groups were evaluated using Fisher’s exact test, 2, or long-rank test
whenever appropriate. Odds ratio (OR) and 95% confidence inter-
vals (CI) are presented. A 2-tailed, paired t test was used to detect
variation within patients. Multivariate logistic regression analysis
was used to study the diagnostic value of the clinical and angio-
graphic without or with Doppler-derived data to predict an optimal
CFVR result. In addition, multivariate regression analysis was
performed to examine the predictive value of the final absolute and
relative CFVR for MACE at 30 days and 1 year. All statistical tests
were 2-tailed, and significance was stated at the 0.05 level.
Results
Baseline Characteristics
Table 1 illustrates the baseline characteristics of the overall
study population. In the overall population (n379), 240
patients seemed to have an optimal CFVR (defined as a
CFVR 2.5) after the intervention, but 139 patients did not
meet this criterion. Patients with an optimal CFVR seemed to
be slightly younger and included a lower percentage of
female patients. No significant differences in drug treatment
before the procedure (aspirin, -blockers, nitrates, and
calcium-channel blockers) were found between patients with
and without an optimal CFVR at the end of the procedure.
Heart rate and double-product values were not significantly
different when comparing patients with and without an
impaired CFVR. A total of 308 patients underwent CFVR
measurements of a reference artery (150 and 158 patients in
the optimal and suboptimal groups, respectively).
TABLE 1. Baseline Characteristics of the Patients With a CFVR
>2.5 and <2.5 at the End of the Procedure
Characteristics
CFVR 2.5
(n240)
CFVR 2.5
(n139) P
Age, y 5710 6111 0.01
Female sex, n (%) 50 (21) 44 (32) 0.03
Diabetes mellitus, n (%) 20 (8) 15 (11) NS
Hypertension, n (%) 83 (35) 56 (40) NS
Hypercholesterolemia, n (%) 122 (57) 67 (48) NS
Previous MI, n (%) 66 (28) 49 (35) NS
Previous angioplasty, n (%) 23 (10) 17 (12) NS
Smoking, n (%) 166 (70) 105 (76) NS
CCS class, n (%)
I/II 87 (36) 45 (32) NS
III/IV 61 (25) 27 (19) NS
Unstable angina, n (%) 71 (30) 55 (40) 0.05
Medication, n (%)
Lipid-lowering 66 (28) 31 (22) NS
Aspirin 212 (88) 119 (86) NS
-Blockade 158 (66) 88 (63) NS
Ca-antagonist 115 (48) 71 (51) NS
Nitrate 157 (65) 87 (63) NS
Hemodynamics
Heart rate, bpm 6812 6912 NS
Double product, mm Hg/bpm 64201623 62191511 NS
Values are meanSD or n (%). CCS indicates Canadian Cardiovascular
Society.
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Coronary Flow Data in the Optimal and
Suboptimal CFVR Groups
As shown in Table 2, patients with a CFVR 2.5 after PTCA
had a lower baseline average peak flow velocity (APV; 189
versus 229 cm/s; P0.05) and a higher hyperemic peak
flow velocity (4818 versus 4318 cm/s; P0.05) in the
target artery. In addition, patients with a CFVR 2.5 had
higher CFVR values in the reference artery than patients with
a CFVR 2.5 (3.100.77 versus 2.450.60; P0.001) due
to a lower baseline APV in the reference artery (147 versus
219 cm/s; P0.05). Relative CFVR was lower in patients
with a CFVR 2.5 after completion of the procedure
(0.810.25 versus 1.010.34; P0.001). No difference was
seen in the angiographic result of the intervention between
the 2 groups. Patients with unstable angina had lower CFVR
values in the reference and target arteries after PTCA than
patients with stable angina (2.730.78 versus 2.930.77 and
2.530.79 versus 2.740.80, respectively; both P0.05). A
total of 144 patients (75%) of the patients with a CFVR 2.5
and 52 (45%) of the patients with a CFVR2.5 had a relative
CFVR 0.8 after the intervention (P0.001). Figure 1
illustrates the significant linear relationship observed between
the CFVR after PTCA and the reference artery CFVR
(P0.001).
Cardiac Enzyme Analysis After the Intervention
The level of total creatine kinase (CK) was increased in the
patients with a CFVR 2.5 after PTCA compared with
patients with a CFVR 2.5 (103233 versus 6148 IU/L;
P0.03). Likewise, levels of CK-MB were increased in
patients with a suboptimal result (1115 versus 66 IU/L;
P0.011).
Patients With Prior MI
A total of 37 patients with a Q-wave MI in the non-target
vascular territory and 78 patients with previous non-Q-wave
MI in the target or nontarget vascular territory were included.
These patients with a history of MI had a slightly lower
CFVR at the end of the procedure compared with patients
without prior MI (2.540.7 versus 2.720.8; P0.05).
Nevertheless, the percentage of MACE in the patients with
prior MI was similar to that in the patients without a history
of MI during 12 months of follow-up (18 of 115 patients
[16%] versus 36 of 264 patients [14%]; PNS]. Furthermore,
patients who had a history of MI in combination with a
decreased CFVR (2.5) at the end of the intervention did not
have an increased percentage of MACE compared with
patients with a decreased CFVR without prior MI (10 of 49
patients [20%] versus 18 of 90 patients [20%]; PNS].
Multivariate Predictors of an Optimal CFVR
After Balloon Angioplasty
The patients with optimal CFVR results after balloon angio-
plasty were younger (5810 versus 6111 years; P0.05),
had a lower proportion of women (20% versus 33%;
P0.005), a lower baseline heart rate (6611 versus 7012
bpm; P0.001), and a higher diastolic blood pressure
(7516 versus 7213 mm Hg; P0.022) than those in the
suboptimal CFVR group. The optimal group presented with a
higher baseline CFVR in the target artery (1.730.62 versus
1.470.39; P0.0001) and in the reference artery
(3.090.72 versus 2.500.64; P0.0001) compared with the
suboptimal group.
By multivariate analysis, an elevated diastolic blood pres-
sure and the absence of unstable angina were found to be the
independent clinical predictors of an optimal CFVR result
after balloon angioplasty (Table 3). However, after including
Doppler-derived data, an elevated diastolic blood pressure
and the CFVR values before angioplasty and in the reference
artery were found to be the only independent predictors of an
optimal balloon CFVR.
Multivariate Predictors of an Optimal CFVR
After Stent Implantation
Patients with optimal CFVR results after stent implantation
were younger (5610 versus 6011 years; P0.024), had a
TABLE 2. Doppler-Derived Data of the Patients With and Without an Optimal CFVR After PTCA
CFVR 2.5 (n240) CFVR 2.5 (n139)
Reference Before PTCA After PTCA Reference Before PTCA After PTCA
Diameter stenosis, %    6811 1511*    7011 1611*
Relative CFVR    0.600.27 1.010.34*†    0.580.18 0.810.25*
CFVR 3.100.77† 1.710.64† 3.120.62*† 2.450.60 1.470.36 1.900.37*
Baseline APV 147† 147 189*† 219 158 229*
Hyperemic APV 4818 2314 4818*† 4720 2111 4318*
*P0.05 vs before PTCA in the same group; †P0.05 vs simultaneous measurements in suboptimal group (CFVR 2.5).
Figure 1. Linear relationship between reference CFVR and
CFVR in the target artery after stenting (R0.495; P0.001).
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lower proportion of smokers (53% versus 70%; P0.017),
and presented with a higher diastolic blood pressure (7613
versus 7112 mm Hg; P0.024) than the suboptimal group.
Moreover, higher CFVRs at baseline (1.700.68 versus
1.460.33; P0.0001), after angioplasty (3.130.71 versus
1.890.50; P0.0001), and at the reference artery
(3.110.83 versus 2.410.56; P0.0001) were consistently
found in the optimal versus the suboptimal stent CFVR
group.
In addition, the optimal stent group had a greater propor-
tion of eccentric lesions than in the suboptimal group (45%
versus 26%; P0.011). After adjusting for clinical variables,
an elevated diastolic blood pressure and the absence of
eccentric lesions were found to be associated with an optimal
CFVR result after stent implantation (Table 4). After includ-
ing Doppler-derived variables, the absence of eccentric le-
sions and elevated values of diastolic blood pressure and
CFVR values before angioplasty and at the reference artery
were found to be independent predictors of an optimal stent
CFVR result.
Independent Predictors of Early and Late
Clinical Outcome
During the first 30 days, the event-free survival was 98% for
all patients, 99% (1 event) for those with a CFVR 2.5, and
96% (7 events) for those with a CFVR 2.5 (P0.024). All
these early events occurred during the first 24 hours (1 patient
died, 4 patients underwent a repeat angioplasty, and 3 patients
had a periprocedural MI).
The ORs for MACE at 30 days and at 1 year for a CFVR
2.5 compared with a CFVR 2.5 were 9.2 (95% CI, 1.1 to
75) and 1.9 (95% CI, 1.1 to 3.4), respectively. After 30 days,
no significant difference in event-free survival was observed
between patients with and without an optimal CFVR at the
end of the procedure (90% versus 85%; P0.139).
The 1-year event-free survival was 86% for all patients,
90% for those with a CFVR 2.5, and 82% for those with a
CFVR 2.5 at the end of the procedure (P0.014 by
log-rank test). Figure 2 shows the estimated event-free
survival distribution according to the CFVR results at the end
of the intervention.
By multivariate logistic analysis, a final CFVR 2.5 was
an independent predictor of MACE at 30 days [OR, 4.71;
95% CI, 1.14 to 25.92; P0.034] and 1-year follow-up (OR,
2.06; 95% CI, 1.16 to 3.66; P0.014). In addition, final
diameter stenosis was an independent predictor of MACE at
1-year follow-up (OR, 1.04; 95% CI, 1.01 to 1.06; P0.03).
Discussion
The results of this study show that a suboptimal result after
angioplasty (CFVR 2.5) is associated with a high risk of
early cardiac events. A low CFVR after PTCA was deter-
mined by the CFVR before PTCA and the CFVR in the
reference artery, which suggest that preexisting microvascu-
lar disturbances were a cause of the low CFVR. Furthermore,
the association with elevated CK and CK-MB values suggest
that microembolization may also explain a low CFVR at the
end of the intervention.
Determinants of Impaired CFVR
After Angioplasty
In agreement with several studies,5–7 we found an elevation of
baseline APV as a contributing factor for a low postproce-
TABLE 3. Multivariate Predictors of an Optimal CFVR After Balloon Angioplasty
Variables*
Clinical Data Alone Clinical and Doppler
OR (95% CI) P OR (95% CI) P
Unstable angina 0.45 (0.23 to 0.90) 0.023      
Diastolic blood pressure 1.02 (1.01 to 1.04) 0.002 1.04 (1.01 to 1.08) 0.012
Baseline CFVR       2.26 (1.57 to 3.24) 0.001
Baseline reference
CFVR
      1.90 (1.21 to 2.98) 0.001
*Variables include sex, diabetes, hypertension, previous MI or revascularization, baseline heart
rate, systolic blood pressure, and diameter stenosis. Lesion characteristics (angulation, calcification,
bifurcation, and contour) were not independent predictors.
TABLE 4. Multivariate Predictors of an Optimal CFVR After Stent Implantation
Variables*
Clinical Data Alone Clinical and Doppler
OR (95% CI) P OR (95% CI) P
Diastolic blood pressure 1.04 (1.01 to 1.06) 0.009 1.06 (1.02 to 1.10) 0.004
Eccentric lesion 0.39 (0.20 to 0.76) 0.006 0.31 (0.13 to 0.77) 0.012
Baseline CFVR       2.54 (1.47 to 4.36) 0.001
Baseline reference
CFVR
      1.97 (1.07 to 3.87) 0.024
*Variables include age, sex; and a history of diabetes, hypertension, smoking, previous MI, or
revascularization. Functional angina class; baseline heart rate, systolic blood pressure, and diameter
stenosis; and lesion characteristics (angulation, calcification, bifurcation, and contour) were not
independent predictors.
1576 Circulation April 2, 2002
dural CFVR. Several mechanisms have been postulated for
this finding, including (1) epicardial vasoconstriction,8 (2)
delay in the recovery of autoregulation,1 (3) distal emboliza-
tion of microparticles,9 and (4) postocclusive hyperemia. Our
data show that a low CFVR after PTCA is determined by the
CFVR before PTCA and the CFVR of the reference artery.
This phenomenon may be related to several clinical condi-
tions associated with microvascular abnormalities (eg, diabe-
tes mellitus, left ventricular hypertrophy, and diffuse athero-
sclerotic disease). Furthermore, our results show elevated CK
and CK-MB levels in patients with an impaired CFVR after
PTCA. This suggests that microembolization may serve as an
alternative explanation for the observed microcirculatory
disturbances.
Animal and human data have shown an enhanced coronary
flow after miocroembolization.10,11 This phenomenon seems
to be due to adenosine-induced hyperemia of the myocardium
surrounding the embolized microregions.12 This interpreta-
tion is further supported by a study reporting that patients
who experienced a prolonged hyperemic response after a
percutaneous intervention had higher creatine phosphokinase
values than patients without hyperemia.13 Similar to those
findings, we found a significant difference in cardiac enzyme
levels between the patients with an optimal and suboptimal
postprocedural CFVR value.
In our study, a low hyperemic response was also respon-
sible for a suboptimal CFVR after balloon angioplasty. The
latter has been previously reported, thus underscoring the
important role of luminal enlargement for the achievement of
an adequate CFVR after balloon angioplasty.6,14
We found a significant relationship between the target and
the reference artery CFVR after stent implantation, further
supporting the concept of a strong influence exerted by the
microcirculation on the postprocedural CFVR results. There-
fore, a combination of microvascular dysfunction and the
severity of the residual stenosis seem to explain a suboptimal
CFVR result after angioplasty. After stent implantation,
normalization of the CFVR seems to depend primarily on the
integrity of the microcirculatory function.
Determination of left ventricular ejection fraction was not
performed before the inclusion of the DEBATE II trial.
Patients were excluded if they had an ejection fraction30%.
Furthermore, patients were excluded if they had a Q-wave MI
in the target vascular territory. However, it is conceivable that
the cohort of patients with a Q-wave MI in the nontarget
vascular territory or with a previous non–Q-wave MI in the
target or nontarget vascular territory included patients with
mildly impaired left ventricular function. Analysis showed
that the patients with a history of MI (and probably mildly
impaired left ventricular function) had a slightly lower CFVR
at the end of the procedure compared with patients without
prior MI. Nevertheless, the percentage of MACE in the
patients with prior MI was similar to that in the patients
without a history of MI.
Impaired CFVR After Angioplasty in Relation to
Clinical Outcome
In the present study, we observed that the early risk of MACE
among the patients with a CFVR 2.5 at the end of the
intervention was 9 times as high as that among the patients
with an optimal CFVR. After excluding 30-day MACE, no
differences in MACE at 1-year follow-up was observed
between the patients with and without a CFVR 2.5 at the
end of the procedure. Thus, low postprocedural CFVR was
associated with a worse periprocedural outcome, although
there was no significant difference at late follow-up.
Although the methods used for the evaluation of the
clinical outcome were different between our study and
DEBATE I, an agreement in short-term results was observed
between both studies. In DEBATE I, a postprocedural CFVR
2.5 was associated with a higher recurrence of angina (25%
versus 12%; P0.19) and a greater proportion of patients
with objective evidence of ischemia (21% versus 8%;
P0.018) at the 1-month follow-up compared with their
counterparts.
It is conceivable that the elevated risk of early events
observed in patients with an impaired postprocedural CFVR
was not only related to the residual stenosis geometry but also
to microvascular alterations. A low CFVR after PTCA, as an
independent predictor of clinical outcome, was determined by
the CFVR before PTCA and the CFVR of the reference
artery. This suggests that the preexisting microcirculatory
disturbances of both the target and reference artery may
influence clinical outcome after PTCA. Furthermore, the
observed elevated cardiac enzyme levels in patients with an
impaired CFVR after PTCA suggest that microembolization
may serve as an alternative explanation for the observed
microcirculatory disturbances and consequent worse clinical
outcome.
Recent data showed that the relative CFVR seems to be a
more specific index of persistent conduit obstruction, which
may have a role in the postprocedural stratification of the
coronary blood flow impairments.4,5 A good long-term out-
come has recently been reported after stent implantation in
patients with a relative CFVR 0.88 and minimal luminal
diameter 2.77 mm.15 Moreover, relative CFVR may iden-
tify patients with global microcirculatory disease. However,
relative CFVR was not a predictor of CFRV after balloon
Figure 2. Kaplan-Meier curve of the percentage of event-free
survival in the patients with a CFVR 2.5 and 2.5 after PTCA.
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angioplasty or stent implantation using a univariate analysis.
A suboptimal result after PTCA (CFVR2.5) was associated
with a lower relative CFVR compared with patients with an
optimal result after PTCA. Nevertheless, relative CFVR was
not an independent predictor of clinical outcome after PTCA
in a multivariate analysis. These contrasting results might be
explained by differences in population size. In the latter
study,15 the authors included only 150 patients; 308 patients
with available relative CFVR measurements were included in
the present study. Stratification of coronary flow impairments
according to relative CFVR results assumes a uniform mi-
crocirculatory function.16 However, this might not be the case
even in patients with single-vessel disease.17
Limitations
Limitations in Doppler measurements have been extensively
described.18 In the present study, trans-stenotic guidewire
pressure-derived fractional flow reserve was not routinely
performed. In patients with a low relative CFVR, fractional
flow reserve could have helped us verify the presence of a
significant residual conduit obstruction and further under-
stand the role of the postprocedural relative CFVR in the
guidance of a percutaneous intervention.
The post hoc nature of our analysis prevents us from
drawing definitive conclusions, and a prospective evaluation
is warranted to confirm our results. Furthermore, this study
only included patients with 1-vessel disease and normal left
ventricular function.
Clinical Implications
After angioplasty, an impaired absolute CFVR was mainly
due to microcirculatory abnormalities that may be either
preexisting or caused by periprocedural microembolization.
The presence of an impaired postprocedural CFVR warrants
monitoring patients more closely because this parameter is
associated with a worse short-term clinical outcome, partic-
ularly during the first 24 hours after the procedure.
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